AZN

AstraZeneca plc 16.3% potential upside indicated by Berenberg Bank

AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 16.3% according to Berenberg Bank.AZN.LBerenberg Bank set a target price of 15,000 GBX for the company, which when compared..

August 13, 2024

AstraZeneca Plc completes acquisition of Amolyt Pharma

AstraZeneca plc (LON: AZN) has completed the acquisition of Amolyt Pharma, enhancing its rare disease pipeline and expanding its bone metabolism franchise...

July 15, 2024

Aptamer Group signs agreement with AstraZeneca to explore Optimer delivery vehicles

Aptamer Group plc has partnered with AstraZeneca to evaluate Optimer® binders for targeted siRNA delivery to fibrotic liver cells, aiming to innovate gene therapies...

July 3, 2024

AstraZeneca plc -11.1% potential downside indicated by Deutsche

AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -11.1% according to Deutsche.AZN.LDeutsche set a target price of 11,000 GBX for the company, which when compared to the..

July 1, 2024

AstraZeneca plc -12.0% potential downside indicated by Deutsche

AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -12.0% according to Deutsche.AZN.LDeutsche set a target price of 11,000 GBX for the company, which when compared to the..

June 21, 2024

AstraZeneca’s Imfinzi plus chemotherapy approved in the US for endometrial cancer

AstraZeneca's Imfinzi gains FDA approval for endometrial cancer treatment. Results show significant benefits for patients with dMMR disease...

June 17, 2024

AstraZeneca plc -10.1% potential downside indicated by Jefferies

AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -10.1% according to Jefferies.AZN.LJefferies set a target price of 11,300 GBX for the company, which when compared to the..

June 6, 2024

AstraZeneca completes acquisition of Fusion Pharmaceuticals

AstraZeneca completes acquisition of Fusion Pharmaceuticals, enhancing its oncology portfolio with next-gen radioconjugates. Learn more here...

June 5, 2024

AstraZeneca Plc Tagrisso recommended for approval in the EU for NSCLC treatment

AstraZeneca's Tagrisso recommended EU approval for 1st-line treatment of EGFRm NSCLC with positive results from FLAURA2 trial published in NEJM...

June 3, 2024

AstraZeneca Plc aims for $80 billion in revenue by 2030

AstraZeneca plc (LON:AZN) has revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth..

May 21, 2024

AstraZeneca to build $1.5 Billion ADC manufacturing facility in Singapore

AstraZeneca plans $1.5 billion ADC manufacturing facility in Singapore, boosting global supply of cancer treatments. Learn more about this greenfield investment...

May 20, 2024

AstraZeneca plc 6.7% potential upside indicated by Berenberg Bank

AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 6.7% according to Berenberg Bank.Berenberg Bank set a target price of 13,000 GBX for the company, which when compared..

May 17, 2024

AstraZeneca’s Sipavibart shows promising results in COVID-19 prevention trial

AstraZeneca's sipavibart shows promising results in Phase III COVID-19 prevention trial for immunocompromised patients, reducing symptomatic cases significantly. A potential game-changer in protecting vulnerable populations...

May 16, 2024

AstraZeneca plc 6.6% potential upside indicated by Berenberg Bank

AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 6.6% according to Berenberg Bank.Berenberg Bank set a target price of 13,000 GBX for the company, which when compared..

May 9, 2024

AstraZeneca Plc completes equity investment with Cellectis

AstraZeneca plc (LON:AZN) completes equity investment with Cellectis, aiming to develop innovative cell and gene therapy products for various medical needs...

May 7, 2024

AstraZeneca plc -13.2% potential downside indicated by Deutsche

AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -13.2% according to Deutsche.Deutsche set a target price of 10,500 GBX for the company, which when compared to the..

May 3, 2024

AstraZeneca plc -13.0% potential downside indicated by Deutsche

AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -13.0% according to Deutsche.Deutsche set a target price of 10,500 GBX for the company, which when compared to the..

April 26, 2024

AstraZeneca plc -13.0% potential downside indicated by Deutsche

AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -13.0% according to Deutsche.Deutsche set a target price of 10,500 GBX for the company, which when compared to the..

April 26, 2024

AstraZeneca plc 13.8% potential upside indicated by Barclays

AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 13.8% according to Barclays.Barclays set a target price of 12,500 GBX for the company, which when compared to the..

April 12, 2024

AstraZeneca Plc to increase Dividend by 7% for 2024

AstraZeneca plc (LON:AZN) announces a 7% increase in annual dividend for 2024 to $3.10 per share, reflecting confidence in performance and cash generation...

April 11, 2024

News and Interview Alerts

Company Presentations

Cerillion plc Overview and Annual Results by CEO & CFO

Likewise Group Tony Brewer: Capturing beyond 10% of £2 billion flooring market (Video)

East Imperial Plc 2023 interims and strategic plans by Tony Burt, CEO

Valeura Energy Q2 2023 Results by Sean Guest CEO

Q&As

Ilika’s Graeme Purdy on first commercial Stereax electrode delivery (LON:IKA)

14 March 2026

Hardman & Co

ICG Enterprise Trust FY’26 results: look to future realisations

11 June 2026

NB Private Equity Partners 2025 results: Looking to future realisations

29 May 2026

Chesnara Plc: Showing good operational progress

17 April 2026

Arbuthnot Banking Group Plc: 2025 lower margins, 2026 profit stability

1 April 2026

Green News

Thor Energy reports elevated hydrogen results at HY-Range project

9 June 2026

Drax agrees £548m cash acquisition of Bluefield Solar Income Fund

1 June 2026

Drax completes commissioning of Hirwaun Power Station

29 May 2026

Jubilee Metals seeks flexibility to fund Molefe region development

29 May 2026

View all Sustainable sectors, Plcs and news >>

Search

Latest Interviews

Real Estate Credit Investments: 10% Yield Strategy Backed by Senior Secured Property Lending (Video)

BrokerTalk

Record’s Inflows Reinforce Confidence in Growth Pipeline

27 April 2026

Cora Gold Funding Deal Takes Sanankoro to Fully Funded Status, Says Hannam & Partners

24 April 2026

Norcros plc reports good progress as FY26 matches expectations, Equity Development

23 April 2026

Primary Health Properties 7.6% yield backed by “Accretive Earnings”, says Shore Capital (LON: PHP)

22 April 2026

Funds

Diverse Income Trust: UK equity outlook and reconstruction proposal (LON:DIVI)

11 June 2026

Biotech Growth Trust reports strong one-year performance

11 June 2026

Ruffer Investment Company delivers positive year-to-date gains

11 June 2026

Finsbury Growth & Income Trust highlights portfolio value in May

9 June 2026

GSK to acquire Biotech Growth Trust portfolio company Nuvalent for $10.6bn

9 June 2026

View all Funds, Market Insights and news >>

FTSE 100 News

Kingfisher confirms full-year guidance after resilient Q1

26 May 2026

Melrose Industries’ GKN Garden Grove MMA tank incident update

26 May 2026

AstraZeneca’s Enhertu recommended for EU approval in HER2-positive solid tumours

26 May 2026

Games Workshop expects core revenue of at least £625m for FY2026

22 May 2026

UK Broker Ratings

Goodwin PLC (GDWN.L) Stock Analysis: A Hidden Gem in Specialty Industrial Machinery with Robust Revenue Growth

9 June 2026

FirstGroup PLC (FGP.L) Stock Analysis: Examining a Potential 50% Upside for Investors

9 June 2026

Chemring Group PLC (CHG.L) Stock Analysis: Aerospace & Defense Player with a 22% Upside Potential

9 June 2026

Hilton Food Group PLC (HFG.L) Stock Analysis: Uncovering a 34.97% Potential Upside in the Packaged Foods Sector

9 June 2026

ABERDEEN GROUP PLC (ABDN.L) Stock Analysis: Navigating the Investment Landscape with a 6.12% Dividend Yield

9 June 2026

AZN

AstraZeneca plc 16.3% potential upside indicated by Berenberg Bank

August 13, 2024

AstraZeneca Plc completes acquisition of Amolyt Pharma

AstraZeneca plc (LON: AZN) has completed the acquisition of Amolyt Pharma, enhancing its rare disease pipeline and expanding its bone metabolism franchise...

July 15, 2024

Aptamer Group signs agreement with AstraZeneca to explore Optimer delivery vehicles

Aptamer Group plc has partnered with AstraZeneca to evaluate Optimer® binders for targeted siRNA delivery to fibrotic liver cells, aiming to innovate gene therapies...

July 3, 2024

AstraZeneca plc -11.1% potential downside indicated by Deutsche

July 1, 2024

AstraZeneca plc -12.0% potential downside indicated by Deutsche

June 21, 2024

AstraZeneca’s Imfinzi plus chemotherapy approved in the US for endometrial cancer

AstraZeneca's Imfinzi gains FDA approval for endometrial cancer treatment. Results show significant benefits for patients with dMMR disease...

June 17, 2024

AstraZeneca plc -10.1% potential downside indicated by Jefferies

June 6, 2024

AstraZeneca completes acquisition of Fusion Pharmaceuticals

AstraZeneca completes acquisition of Fusion Pharmaceuticals, enhancing its oncology portfolio with next-gen radioconjugates. Learn more here...

June 5, 2024

AstraZeneca Plc Tagrisso recommended for approval in the EU for NSCLC treatment

AstraZeneca's Tagrisso recommended EU approval for 1st-line treatment of EGFRm NSCLC with positive results from FLAURA2 trial published in NEJM...

June 3, 2024

AstraZeneca Plc aims for $80 billion in revenue by 2030

May 21, 2024

AstraZeneca to build $1.5 Billion ADC manufacturing facility in Singapore

AstraZeneca plans $1.5 billion ADC manufacturing facility in Singapore, boosting global supply of cancer treatments. Learn more about this greenfield investment...

May 20, 2024

AstraZeneca plc 6.7% potential upside indicated by Berenberg Bank

May 17, 2024

AstraZeneca’s Sipavibart shows promising results in COVID-19 prevention trial

May 16, 2024

AstraZeneca plc 6.6% potential upside indicated by Berenberg Bank

May 9, 2024

AstraZeneca Plc completes equity investment with Cellectis

AstraZeneca plc (LON:AZN) completes equity investment with Cellectis, aiming to develop innovative cell and gene therapy products for various medical needs...

May 7, 2024

AstraZeneca plc -13.2% potential downside indicated by Deutsche

May 3, 2024

AstraZeneca plc -13.0% potential downside indicated by Deutsche

April 26, 2024

AstraZeneca plc -13.0% potential downside indicated by Deutsche

April 26, 2024

AstraZeneca plc 13.8% potential upside indicated by Barclays

April 12, 2024

AstraZeneca Plc to increase Dividend by 7% for 2024

AstraZeneca plc (LON:AZN) announces a 7% increase in annual dividend for 2024 to $3.10 per share, reflecting confidence in performance and cash generation...

April 11, 2024